Table 1.
Patient, disease, and prior treatment characteristics.
| Na (total = 22) | % | |
|---|---|---|
| Histology | ||
| Endometrioid | 18 | 81.8% |
| Papillary serous or dear cell | 4 | 18.2% |
| Median age at time of re-irradiation (range) | 71(49–90) | - |
| 2009 FIGO stage at diagnosis | ||
| IA | 8 | 36.4% |
| IB | 5 | 22.7% |
| II | 3 | 13.6% |
| IIIA | 3 | 13.6% |
| IIIC1 or IIIC2 | 3 | 13.6% |
| Grade at diagnosis | ||
| Grade 1 | 6 | 27.3% |
| Grade 2 | 11 | 50.0% |
| Grade 3 | 5 | 22.7% |
| Presence of LVS1 at diagnosis | ||
| Yes | 8 | 36.4% |
| No | 9 | 40.9% |
| Unknown | 5 | 22.7% |
| Prior pelvic radiation type | ||
| Vaginal brachytherapy | 12 | 54.5% |
| Pelvic EBRT | 5 | 22.7% |
| Pelvic EBRT + vaginal brachytherapy | 5 | 22.7% |
| Median prior EBRT dose (Gy) (range) | 45 (30.6–50.4) | - |
| Prior brachytherapy dose regimen | ||
| 21 Gy in 3 fractions | 9 | 40.9% |
| 30 Gy in 6 fractions | 2 | 9.1% |
| 10 Gy in 2 fractions | 2 | 9.1% |
| Other | 4 | 18.2% |
| Prior chemotherapy | ||
| Adjuvant | 5 | 22.7% |
| Neoadjuvant | 1 | 4.5% |
| Salvage | 1 | 4.5% |
| Median re-irradiation interval (months) (IQR) | 26.6 (17.2–54.4) | - |
a
Unless otherwise specified. LVSI — lymphovascular space invasion. EBRT — external beam radiation therapy. IQR = interquartile range.